| Autor: |
Jabbour, E., Koscielny, S., Sebban, C., Peslin, N., Patte, C., Gargi, T., Biron, P., Fermé, C., Bourhis, J. H., Vantelon, J. M., Arnaud, P., Ribrag, V. |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); May2006, Vol. 20 Issue 5, p814-819, 6p, 2 Charts, 4 Graphs |
| Abstrakt: |
The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 protocol previously reported in pediatric patients. The median age was 31 years. Mediastinal enlargement was present in 25/27 patients, with pleural effusion in 12. Four patients had central nervous system involvement and 12 had bone marrow involvement and 24/27 (89%) had advanced Ann Arbor stage III–IV disease. Complete remission (CR) was achieved in 20/27 patients, unconfirmed complete remission in three patients (residual mediastinal lesion on computed tomography scan) and four failed induction therapy (ORR: 85%). Twelve patients (44%) remained in continuous CR with a median follow-up of 95 months. Survival at 3 years (when all the events occurred in our series) was 63%. Bone marrow involvement was associated with a poor outcome. Overall survival was 85±20% in patients without bone marrow involvement compared to 37±30% in patients with bone marrow involvement. The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes. This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement.Leukemia (2006) 20, 814–819. doi:10.1038/sj.leu.2404156; published online 2 March 2006 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
